Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Advance PCS To Step Up Mail Order, "Re-Contract" For Higher Rebates

  • News

Executive Summary

The sale of PCS to Advance Paradigm could lead to a significant ramping up of the mail service side of the pharmacy benefit management company.

You may also be interested in...



Rite Aid To Gain Specialty Drug, Part D Platforms With PBM EnvisionRx

The drug store chain will purchase EnvisionRx, which serves over 21 million members and expects to manage 145 million pharmacy claims in 2015, for $2 billion in cash and stock.

Rite Aid Examining Third-Party Prescription Contracts To Improve Margins

Rite Aid is focusing on third-party prescription drug contracts as an area to improve profit margins.

Rite Aid Examining Third-Party Prescription Contracts To Improve Margins

Rite Aid is focusing on third-party prescription drug contracts as an area to improve profit margins.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS036330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By